Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

High $1.17	Low $1.13	Trades 1,304	Turnover $2,983,889	Volume 2,606,681
30 June 2023 at 4:10pm

If you were already registered, log in here.

Market Cap (13-Nov) $2,538,662,912 (333rd)	Close (30-Jun) $1.14 0 (0%)	Volume (30-Jun) 2,606,681	Shortsold (9-Nov) 93,269,774 (7.17%) (40th)
52w High $3.31	52w Low $1.74	P/E 454.55	EPS -0.07

Short Interest

ASIC data, 9 Nov 2026

% Shorted

7.17% 0.01

vs 7.18% prior report

Most Shorted Rank

40th

of 711 shorted ASX stocks

Peak Short

11.00%

Oct 2015

Days to Cover

28.4

at 50d avg vol

View full short position history →

	Subject
	MSB MSB Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
	1 (current) 2 3
	MSB MSB Ann: Annual Report to Shareholders
	MSB MSB Ann: Notice of Annual General Meeting and Proxy Form
	MSB MSB Ann: Appendix 4G and Corporate Governance Statement
	MSB MSB Ann: Appendix 4C Quarterly Activity Report
	MSB MSB Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD
	MSB MSB Ann: Notification of cessation of securities - MSB
	MSB MSB Ann: Notification regarding unquoted securities - MSB
	MSB MSB Ann: CHF Late Breaker Presentation at American Heart Association
	MSB MSB Article: Mesoblast says FDA has not put a ‘hold’ on drug trial
	MSB MSB Article: Mesoblast shares dive 16pc as FDA raises more questions
	MSB MSB Ann: MSB Annual Financial Results and Operational Progress
	MSB MSB Ann: Annual Financial Results Presentation
	MSB MSB Ann: Preliminary Final Report including Appendix 4E
	MSB MSB Ann: Appendix 3G and 3H
	MSB MSB Ann: Mesoblast 2021 Full Year Financial Results Webcast
	MSB MSB Article: Mesoblast loses its CFO
	MSB MSB Ann: Mesoblast Management Update
	MSB MSB Article: Ownership Matters tallies up Mesoblast cash outflows, raises
	MSB MSB Ann: Appendix 4C Quarterly Activity Report
	MSB MSB Ann: Release of Shares from Voluntary Escrow
	MSB MSB Article: Mesoblast boss won’t answer share deal questions
	MSB MSB Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT
	MSB MSB Ann: COVID ARDS Trial Respiratory Outcomes Presented
	MSB MSB Ann: COVID ARDS Trial Results Presentation
	MSB MSB Ann: Appendix 3Y - Change of Director's Interest Notice
	MSB MSB Ann: Appendix 3G
	MSB MSB Article: Mesoblast, Grünenthal downgrade partnership deal
	MSB MSB Ann: Mesoblast Update on Chronic Low Back Pain Program
	MSB MSB Ann: MSB Reports Q3 Financial Results and Operational Highlight
	MSB MSB Ann: Third Quarter Results Presentation
	MSB MSB Ann: Third Quarter Financial Results on Form 6-K
	MSB MSB Ann: Mesoblast Q3 Financial Results Webcast
	MSB MSB Ann: Remestemcel-L for COPD Published in Respiratory Research
	MSB MSB Article: Mesoblast’s selective disclosure continues
	MSB MSB Ann: COVID ARDS Trial Topline 60-Day Results
	MSB MSB Ann: Appendix 4C Quarterly Activity Report
	MSB MSB Ann: Mesoblast Corporate Update Webcast
	MSB MSB Article: Mesoblast may face fresh class action claim in Australia
	MSB MSB Ann: Director's Interest Notice - Appendix 3X
	MSB MSB Ann: Mesoblast Operational Highlights and Upcoming Milestones
	MSB MSB Ann: Director Appointment/Resignation
	MSB MSB Ann: Prospectus for Warrants in Connection with US$110M Raise
	MSB MSB Ann: MSB Closes US$110M Raise Led By US Strategic Investor Group
	MSB MSB Ann: Cleansing Notice and Appendix 2A
	MSB MSB Ann: Cleansing Notice and Appendix 2A
	MSB MSB Article: Mesoblast gets a new lifeline via $138m finance deal
	MSB MSB Article: ASX gains ahead of RBA meeting
	MSB MSB Ann: Proposed issue of Securities - MSB
	MSB MSB Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group

If you were already registered, log in here.

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

Upcoming Floats (8)

MATRIX CRITICAL MINERALS LIMITED

MTX

SUPER MINERALS LTD

S88

MAVERICK URANIUM LIMITED

MAV

Fitgenes

ATW $7.5m raise

RIO DE ORO CORP LTD

RDO $30m raise

Adbri Ltd

ABC $5m raise

RAMSAY GENERALE DE SANTE SA

RGS

Gratifii

MBM

Top

End of Day Prices

Date	Close	Volume	Change
13-Nov	$1.93	2,543,962	-0.03 (1.28%)
12-Nov	$1.96	3,137,996	-0.07 (3.69%)
11-Nov	$2.03	1,587,374	-0.05 (2.40%)
10-Nov	$2.08	2,613,105	+0.04 (1.96%)
09-Nov	$2.04	2,285,102	+0.01 (0.49%)
06-Nov	$2.03	2,423,463	-0.14 (6.45%)
05-Nov	$2.17	2,953,496	+0.07 (3.33%)
04-Nov	$2.10	2,601,657	-0.06 (2.78%)
03-Nov	$2.16	1,560,746	0.00 (0.00%)
02-Nov	$2.16	4,396,629	-0.10 (4.42%)
30-Oct	$2.26	3,452,259	-0.06 (2.59%)
29-Oct	$2.32	13,592,793	+0.44 (23.40%)
28-Oct	$1.88	2,650,500	+0.02 (1.35%)
27-Oct	$1.86	3,071,957	+0.07 (3.92%)
26-Oct	$1.79	1,315,866	+0.01 (0.56%)
7 up, 7 down, and 1 flat days

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Mesoblast Health Care Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology